BCYC241220C15000
- 8.88
- 0.000.00%
Bicycle Therapeutics Newsroom
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
Stephens Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $25
Stephens Sees 'Uphill Battle' for Bicycle Therapeutics, Starts at Equal Weight
Morgan Stanley Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $30
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
Bicycle Therapeutics Plc (NASDAQ:BCYC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
JMP Securities Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $32
Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $55
RBC Capital Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $35
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | RBC Capital Reiterates Outperform on Bicycle Therapeutics, Maintains $35 Price Target
Bicycle Therapeutics Analyst Ratings
Bicycle Therapeutics GAAP EPS of -$0.74 Beats by $0.02, Revenue of $2.68M Misses by $4.33M
Bicycle Therapeutics | 10-Q: Q3 2024 Earnings Report
Bicycle Therapeutics | 8-K: Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Express News | Bicycle Therapeutics PLC: Expected Financial Runway Into 2H 2027
Bicycle Therapeutics 3Q Rev $2.68M >BCYC
Press Release: Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Express News | Bicycle Therapeutics Q3 Pretax Profit USD -54.25 Million